Z Gastroenterol 2002; 40(11): 937-943
DOI: 10.1055/s-2002-35412
Übersicht
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Gastrointestinale Nebenwirkungen der Therapie rheumatischer Erkrankungen

Gastrointestinal Side Effects in the Therapy of Rheumatologic DiseasesU. Schiemann1 , H. Kellner1
  • 1Medizinische Poliklinik, Klinikum der Universität München - Innenstadt, Ludwig-Maximilians-Universität München
Further Information

Publication History

Publication Date:
18 November 2002 (online)

Zusammenfassung

Die weit verbreitet eingesetzten Antirheumatika können eine Vielzahl gastrointestinaler Komplikationen hervorrufen. Sympto­matische Therapeutika wie Glukokortikoide und nicht-steroidale Antirheumatika sind bekannt für das Auftreten von Magen- und Duodenalulzera, besonders unter ihrer Kombinationsbehandlung. Das Nebenwirkungsspektrum der Basistherapeutika (Methotrexat, Leflunomid, Hydroxy-/Chloroquin, Sulfasalazin) umfasst neben unspezifischen gastrointestinalen Reizsymptomen wie Übelkeit, Erbrechen und Diarrhöen auch die Induktion von ulzerösen Schleimhautläsionen (Methotrexat) und vor allem das Auftreten einer Hepatopathie. Diese kann sich durch eine asymptomatische Erhöhung der Transaminasen oder Cholestaseparameter manifestieren, jedoch in Einzelfällen unter einer Monotherapie (Hydroxy-/Chloroquin, Sulfasalazin), besonders aber unter einer Kombina­tionsbehandlung (Methotrexat + Leflunomid) zur fulminanten Hepatitis führen. Die TNF-α-blockierenden Substanzen (Etanercept, Infliximab) als neue Generation antiinflammatorischer Therapeutika weisen nach derzeitiger klinischer Erfahrung und Datenlage in der Literatur keine relevanten gastrointestinalen Nebenwirkungen auf.

Abstract

Antirheumatic drugs may lead to a number of relevant gastrointestinal complications. Symptomatical treatments with glucocorticoids and non steroidal antirheumatic drugs (NSAD) are known to induce gastric or duodenal ulcers, above all under combination therapies. Side effects of DMARD's (methotrexate, leflunomide, hydroxy/chloroquine, sulfasalazine) include unspecifical gastrointestinal symptoms like nausea, vomiting and diarrhea as well as induction of ulcerative mucosal lesions (methotrexate) and occurrence of a hepatopathy. The latter may appear as an asymptomatical elevation of liver transaminases or cholestase parameters, but can also lead, in some cases of a monothera­py (hydroxy-/chloroqine, sulfasalazine) or combination therapy (methotrexate + leflunomide) to a fulminant hepatitis. TNF-α-inhibiting drugs (etanercept, infliximab) as a new generation of anti-inflammatory therapeutics don't have relevant gastrointestinal side effects according recently published data.

Literatur

  • 1 Smith M D, Ahern M J, Roberts-Thomson P J. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone?.  Ann Rheum Dis. 1988;  47 (1) 28-33
  • 2 Hayball P J, Cosh D G, Ahern M J. et al . High dose oral methylprednisolon in patients with rheumatoid arthritis: pharmacokinetics and clinical response.  Eur J Clin Pharmacol. 1992;  42 (1) 85-88
  • 3 Saag K G. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence.  Am J Med. 1997;  103 (6A) 31S-39S
  • 4 Pearson D, Sheldon P. Effect of corticosteroid on lymphocyte adhe­sion.  Adv Exp Med Biol. 1995;  371A 167-170
  • 5 Aglas F, Rainer F, Lipp R W. et al . Effect of steroid treatment on the migration behaviour of neutrophils in patients with early rheumatoid arthritis.  Rheumatol Int. 1997;  17 (4) 137-140
  • 6 Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs.  FASEB J. 1987;  1 (2) 89-96
  • 7 Saag K G, Koehnke R, Caldwell J R. et al . Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.  Am J Med. 1994;  96 (2) 115-123
  • 8 Hernandez-Diaz S, Rodriguez L A. Steroids and risk of upper gastrointestinal complications.  Am J Epidemiol. 2001;  153 (11) 1089-1093
  • 9 Conn H O, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy.  J Intern Med. 1994;  236 619-632
  • 10 Piper J M, Ray W A, Daugherty J R. et al . Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs.  Ann Intern Med. 1991;  114 735-740
  • 11 Garcia R odriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.  Arthritis Res. 2001;  3 (2) 98-101
  • 12 Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ­ARAMIS database.  Am J Ther. 2000;  7 (2) 115-121
  • 13 Ceuppens J L, Rodriguez M A, Goodwin J S. Non-steroidal anti-inflammatory agent inhibit the synthesis if IgM rheumatoid factor in vitro.  Lancet. 1982;  1 (8271) 528-530
  • 14 Goodwin J S. Mechanism of action of nonsteroidal anti-inflammatory agents.  Am J Med. 1984;  77 (1A) 57-64
  • 15 Daymond T J, Rowell F J. Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumaoid arthritis following tiaprofenic acid or indomethacin treatment.  Drugs. 1988;  35 (Suppl. 1) 4-8
  • 16 Raskin J B. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy.  Am J Med. 1999;  106 (5B) 3S-12S
  • 17 Fries J F, Williams C A, Bloch D A. et al . Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.  Am J Med. 1991;  91 (3) 213-222
  • 18 Stehen K S, Lems W F, Aersen J. et al . Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis.  Ann Rheum Dis. 2001;  60 (5) 443-447
  • 19 Lanas A, Serrano P, Bajador E. et al . Evidence of aspirin use in both upper and lower gastrointestinal perforation.  Gastroenterology. 1997;  112 683-689
  • 20 Wolfe M M, Lichtenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.  N Engl J Med. 1999;  24 1888-1899
  • 21 Cheatum D E, Arvanitakis C, Gumpel M. et al . An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs.  Clin Ther. 1999;  21 (6) 992-1003
  • 22 Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications.  J Rheumatol. 1999;  26 (Suppl. 26) 18-24
  • 23 Schwake L, Schenker T, Schwake S. et al . Ulcers of the colon in association with nonsteroidal anti-inflammatory drugs (NSAID) - a rare cause of gastrointestinal bleeding? Report of 3 cases.  Z Gastroenterol. 2000;  38 (12) 957-961
  • 24 Lugea A, Antolin M, Mourelle M. et al . Deranged hydrophobic barrier of the gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs.  Gastroenterology. 1997;  112 1931-1939
  • 25 Seitz S, Boelsterli U A. Diclofenac acyl glucuronide, a major biliary ­metabolite, is directly involved in small intestinal injury in ras.  ­Gastroenterology. 1998;  115 1476-1482
  • 26 Gut A, Halter F, Ruchti C. Nichtsteroidale Antirheumatika und Azetylsalizylsäure: Nebenwirkungen distal des Duodenums.  Schw Med Wochenschr. 1996;  126 616-623
  • 27 Bridges A J, Marshall J B, Diaz-Arias A A. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy.  Am J Med. 1990;  89 526-527
  • 28 Willett L R, Carson J L, Strom B L. Epidemiology of gastrointestinal damage associated with non-steroidal anti-inflammatory drugs.  Drug Safety. 1994;  10 170-181
  • 29 Gentric A, Pennec Y L. Diclofenac-induced pseudomembranous colitis.  Lancet. 1992;  340 126-127
  • 30 Israel L H, Koea J B, Stewar I D. et al . Nonsteroidal anti-inflammatory drug-induced strictures of the colon: report of a case and review of the literature.  Dis Colon Rectum. 2001;  44 (9) 1362-1364
  • 31 Rooney T W, Furst D E, Koehnke R. et al . Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate.  J Rheumatol. 1993;  20 (8) 1297-1302
  • 32 Koch M, Dezi A, Tarquini M. et al . Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications.  Dig Liver Dis. 2000;  32 (2) 138-151
  • 33 Bianchi P orro G, Lazzaroni M, Imbesi V. et al . Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.  Dig Liver Dis. 2000;  32 (3) 201-208
  • 34 Goldstein J L. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?.  Eur J Gastroenterol Hepatol. 2000;  12 (Suppl. 1) S11-15
  • 35 Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.  Curr Med Chem. 2000;  7 (11) 1121-1129
  • 36 Benson W G, Zhao S Z, Burke T A. et al . Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.  J Rheumatol. 2000;  27 (8) 1876-1883
  • 37 Silverstein F E, Faich G, Goldstein J L. et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.  JAMA. 2000;  284 (10) 1247-1255
  • 38 Bombardier C, Laine L, Reicin A. et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 (21) 1520-1528
  • 39 Goldstein J L, Correa P, Zhao W W. et al . Reduced incidence of gastro­duodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.  Am J Gastroenterol. 2001;  96 (4) 1019-1027
  • 40 Hawkey C J, Tulassay Z, Szczepanski L. et al . Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.  Lancet. 1998;  352 1016-1021
  • 41 Chan F KL, Sung J JY, Chun S CS. et al . Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.  Lancet. 1997;  350 975-979
  • 42 Hawkey C J. What consideration should be given to Helicobacter ­pylori in treating nonsteroidal anti-inflammatory drug ulcers?.  Eur J Gastroenterol Hepatol. 2000;  12 (Suppl. 1) 17-20
  • 43 Chan F KL, To K F, Wu J CY. et al . Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs.  Lancet. 2002;  359 9-13
  • 44 Huang J O, Sridhar S, Hunt R H. Role of Helicobacer pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.  Lancet. 2002;  359 14-22
  • 45 Thompson R N, Watts C, Edelman J. et al . A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis.  J Rheumatol. 1984;  11 760-763
  • 46 Andersen P A, West S G, OŽDell J R. et al . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.  Ann Intern Med. 1985;  103 489-496
  • 47 Weinblatt M E, Coblyn J S, Fox D A. et al . Efficacy of low-dose methotrexate in rheumatoid arthritis.  N Engl J Med. 1985;  312 818-822
  • 48 Williams H J, Willkens R F, Samuelson C OJ. et al . Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.  Arthritis Rheum. 1985;  28 721-730
  • 49 Budzik G P, Colletti L M, Faltynek C R. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.  Life Sci. 2000;  66 2297-2307
  • 50 Hornung N, Stenfaard-Pedersen K, Ehrnrooth E. et al . The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells.  Clin Exp Rheumatol. 2000;  18 691-698
  • 51 Wiewiorowski M, Graczyk J. The effective of methotrexate on immune response cells in rheumatoid arthritis.  Acta Pol Pharm. 2000;  57 (Suppl.) 138-139
  • 52 Mello S B, Barros D M, Silva A S. et al . Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis.  Rheumatology. 2000;  39 533-536
  • 53 Seitz M, Zwicker M, Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment.  J Rheumatol. 2001;  28 496-501
  • 54 Cutolo M, Bisso A, Sulli A. et al . Antiproliferative and antiinflmammatory effects of methotrexae on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis.  J Rheumatol. 2000;  27 2551-2557
  • 55 Wluka A, Buchbinder R, Mylvaganam A. et al . Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.  J Rheumatol. 2000;  27 1864-1871
  • 56 Baehr P H, McDonald G B. Esophageal disorders caused by infection, systemic illness, medications, radiation, and trauma. Feldman M, Scharschmidt BF, Sleisenger MH Gastrointestinal and liver disease. Pathophysiology, diagnosis, management Philadelphia; Saunders 1998: 519-539
  • 57 Sampaio-Barros P D, Costallat L, Berolo M B. et al . Methotrexate in the treatment of ankylosing spondylitis.  Scand J Rheumatol. 2000;  29 160-162
  • 58 Hirshberg B, Muszkat M, Schlesinger O. et al . Safety of low dose methotrexate in elderly patients with rheumatoid arthritis.  Postgrad Med J. 2000;  76 787-789
  • 59 Ito S, Nakazono K, Murasawa A. et al . Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.  Arthritis Rheum. 2001;  44 339-342
  • 60 Scapa E, Yona E, Amram L. Cecal ulceration due to methotrexate.  Isr Med Assoc J. 2001;  3 230
  • 61 Uehara R, Suzuki Y, Ichikawa Y. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy.  J Rheumatol. 2001;  28 251-256
  • 62 Landewe R B, van den Borne B E, Breedveld F C. et al . Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.  Lancet. 2000;  355 1616-1617
  • 63 Bressolle F, Kinowski J M, Morel J. et al . Folic acid alters methotrexate availability in patients with rheumatoid arthritis.  J Rheumatol. 2000;  27 2110-2114
  • 64 Shahin A A, Ismail M M, Saleh A M. et al . Protective effect of folinic acid on low-dose methotrexate genotoxicity.  Z Rheumatol. 2001;  60 63-68
  • 65 Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide InvestigatorsŽ Group.  J Rheumatol Suppl. 1998;  53 27-32
  • 66 Alldred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.  Expert Opin Pharmacother. 2001;  2 125-137
  • 67 Fox R I, Herrmann M L, Frangou C G. et al . Mechanism of action for leflunomide in rheumatoid arthritis.  Clin Immunol. 1999;  93 198-208
  • 68 Strand V, Tugwell P, Bombardier C. et al . Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexat or placebo in patients with active rheumatoid arthritis.  Arthritis Rheum. 1999;  42 1870-1878
  • 69 Strand V, Cohen S, Schiff M. et al . Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methorexat.  Arch Intern Med. 1999;  159 2542-2550
  • 70 Smolen J S, Kalden J R, Scott D L. et al . Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.  Lancet. 1999;  353 259-266
  • 71 Hewitson P J, Debroe S, McBride A. et al . Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications.  J Clin Pharm Ther. 2000;  25 295-302
  • 72 Kraan M C, Reece R J, Barg E C. et al . Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.  Arthritis Rheum. 2000;  43 1820-1830
  • 73 Kraan M C, de Koster B M, Elfereink J G. et al . Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexat in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.  Arthritis Rheum. 2000;  43 1488-1495
  • 74 Emery P, Breedveld F C, Lemmel E M. et al . A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.  Rheumatology. 2000;  39 655-665
  • 75 Schattenkirchner M. The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.  Immunopharmacology. 2000;  47 291-298
  • 76 Coblyn J S, Shadick N, Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis.  Arthritis Rheum. 2001;  44 1048-1051
  • 77 Goldenberg M M. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.  Clin Ther. 1999;  21 1837-1852
  • 78 Kremer J R, Caldwell J R, Cannon G W. et al . Combination of lefkunomide and methotrexate in patients with rheumatoid arthritis.  Arthritis Rheum. 2000;  43 (Suppl. 9) 224: A948
  • 79 Reinhold-Keller E, Gross W L. Leflunomid zur Behandlung der rheumatoiden Arthritis.  Dt Aerzteblatt. 2001;  98 A 1881-1887
  • 80 Husain Z, Runge L A. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole.  J Rheumatol. 1980;  7 (6) 825-830
  • 81 Haar D, Solvkjaer M, Unger B. et al . A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.  Scand J Rheumatol. 1993;  22 (3) 113-118
  • 82 Furst D E, Lindsley H, Baehge B. et al . Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.  Arthritis Rheum. 1999;  42 (2) 357-365
  • 83 Durieux S, Rozenberg S, Bourgeois P. Complications of colonic diverticular disease during rheumatoid poylarthritis: 7 cases.  Rev Med Interne. 1999;  20 (1) 50-53
  • 84 Kim W U, Seo Y I, Park S H. et al . Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis.  Ann Rheum Dis. 2001;  60 (5) 514-517
  • 85 van Riel P L, van Gestel A M, van de Putte L B. Long-term usage and ­side-effect profile of sulphasalazine in rheumatoid arthritis.  Br J Rheumatol. 1995;  34 (Suppl. 2) 40-42
  • 86 Rodenburg R J, Ganga A, van Lent P L. et al . The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis.  Arthritis Rheum. 2000;  43 (9) 1941-1950
  • 87 Hayllar J, Smith T, Macpherson A. et al . Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazin and other disease-modifying antirheumatic drugs.  Arthritis Rheum. 1994;  37 (8) 1146-1150
  • 88 Clohen D O, Reda D J, Weisman M H. et al . Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis.  Arthritis Rheum. 1996;  39 (12) 2004-2012
  • 89 Rojkovich B, Hodinka L, Balint G. et al . Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis.  Scand J Rheumatol. 1999;  28 (4) 216-221
  • 90 Mundo A, Pedone V, Lamanna G. et al . Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis.  Clin Ter. 1997;  148 (1-2) 7-13
  • 91 Jung J H, Jun J B, Yoo D H. et al . High toxicity of sulfasalazine in adult-onset Still's disease.  Clin Exp Rheumatol. 2000;  18 (2) 245-248
  • 92 Weinblatt M E, Kremer J M, Bankhurst A D. et al . A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.  N Engl J Med. 1999;  28: 340 (4) 253-259
  • 93 Moreland L W, Schiff M H, Baumgartner S W. et al . Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.  Ann Intern Med. 1999;  130 (6) 478-486
  • 94 Hamilton K, Clair E W. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.  Expert Opin Pharmacother. 2000;  1 (5) 1041-1052
  • 95 Bathon J M, Martin R W, Fleischmann R M. et al . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.  N Engl J Med. 2000;  343 (22) 1586-1593
  • 96 Lipsky P E, van der Heijde D M, St C lair EW. et al . Infliximab and methotrexate in the treatment of rheumatoid arthritis.  N Engl J Med. 2000;  343 (22) 1594-1602
  • 97 Ulfgren A K, Andersson U, Engstrom M. et al . Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.  Arthritis Rheum. 2000;  43 (11) 2391-2396
  • 98 Schaible T F. Long term safety of infliximab.  Can J Gastroenterol. 2000;  14 (Suppl. C) 29C-32C
  • 99 Baghai M, Osmon D R, Wolk D M. et al . Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.  Mayo Clin Proc. 2001;  76 (6) 653-656
  • 100 Charles P J, Smeenk R J, De Jong J. et al . Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in a open-label and randomized placebo-controlled trials.  Arthritis Rheum. 2000;  43 (11) 2383-2390
  • 101 Russell E, Zeihen M, Wergin S. et al . Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays.  Arthritis Rheum. 2000;  43 (4) 944
  • 102 Bloom B J. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis.  Arthritis Rheum. 2000;  43 (11) 2606-2608
  • 103 Allanore Y, Bremont C, Kahan A. et al . Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept.  Clin Exp Rheumatol. 2001;  19 (3) 356-357
  • 104 Sandborn W J, Hanauer S B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.  Inflamm Bowel Dis. 1999;  5 (2) 119-133
  • 105 Maini R, St C lair EW, Breedveld F. et al . Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate.  Lancet. 1999;  354 1932-1939
  • 106 Kavanaugh A, Keenan G, DeWoody K. et al . Long-term follow-up of patients treated with infliximab in clinical trial.  Arthritis Rheum. 2001;  44 (9) Suppl. Abstract No. 173
  • 107 Gridley G, McLaughlin J K, Ekbom A. et al . Incidence of cancer among patients with rheumatoid arthritis.  J Natl Cancer Inst. 1993;  85 (4) 307-311
  • 108 Baecklund E, Ekbom A, Sparen P. et al . Disease activity and risk of lymphoma in patients with rheumatoid arthritis.  BMJ. 1998;  317 180-181
  • 109 Moreland L W, Cohen S B, Baumgartner S W. et al . Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.  J Rheumatol. 2001;  28 (6) 1238-1244
  • 110 Feldmann M, Maini R N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?.  Annu Rev Immunol. 2001;  19 163-196

Dr. med. Uwe Schiemann

Medizinische Poliklinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität München

Pettenkoferstraße 8a

80336 München

Email: uwe.schiemann@pk-i.med.uni-muenchen.de

    >